Agios Pharmaceuticals (AGIO) Cash from Investing Activities (2012 - 2026)

Agios Pharmaceuticals has reported Cash from Investing Activities for 15 years, with the latest figure at $141.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 25.51% year-over-year to $141.3 million; the trailing twelve-month figure through Mar 2026 stood at $405.9 million (up 15.49% YoY), and the FY2025 full-year result was $377.2 million, up 3.78% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $141.3 million, up from $90.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $250.8 million in Q3 2024, with the low at -$49.2 million in Q4 2024.
• Historically, Cash from Investing Activities has averaged $80.3 million across 5 years, with a median of $83.0 million in 2022.
• The largest YoY upside for Cash from Investing Activities was 537.49% in 2024 against a maximum downside of 151.47% in 2024.
• Agios Pharmaceuticals' Cash from Investing Activities stood at $83.0 million in 2022, then climbed by 15.14% to $95.5 million in 2023, then sank by 151.47% to -$49.2 million in 2024, then surged by 283.24% to $90.1 million in 2025, then soared by 56.88% to $141.3 million in 2026.
• The last three Cash from Investing Activities figures came in at $141.3 million (Q1 2026), $90.1 million (Q4 2025), and $95.6 million (Q3 2025), per Business Quant data.